Share Prices & Company Research

Market News

23 Aug 2019 | 08:40

Hutchison China MediTech begins clinical trials for immune thrombocytopenia drug

Hutchison China MediTech said it had begun a clinical trial for its drug that deals with immune thrombocytopenia, an autoimmune disorder that can lead to increased risk of bleeding.

The first ITP patient was dosed on August 12, 2019 in China.

The study, a randomized, double-blinded, placebo-controlled Phase Ib clinical trial was investigating the safety, tolerability, pharmacokinetics and preliminary efficacy of the company's drug HMPL-523 used to treat adults with immune thrombocytopenia.

The primary endpoint of the study was based on the number of patients with any adverse event. The secondary endpoints were maximum plasma concentration area under the concentration-time curve in a selected time interval and rate of clinical remission at week 8, the company said.

Approximately 50 to 60 patients would be enrolled, the company added.

At 8:40am: (LON:HCM) Hutchison China Meditech Ltd share price was -0.75p at 333.75p

Story provided by
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.